Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$26.70

0.22 (0.83%)

, MSI

Motorola Solutions

$105.89

1.16 (1.11%)

10:14
02/23/18
02/23
10:14
02/23/18
10:14

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) assumed with an Overweight at Piper Jaffray. 2. Motorola Solutions (MSI) resumed with an Outperform at Raymond James. 3. Albemarle (ALB) initiated with a Buy at Argus. 4. New Relic (NEWR) initiated with an Outperform at Wedbush. 5. CTI BioPharma (CTIC) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

BSX

Boston Scientific

$26.70

0.22 (0.83%)

MSI

Motorola Solutions

$105.89

1.16 (1.11%)

ALB

Albemarle

$115.77

2.09 (1.84%)

NEWR

New Relic

$71.29

0.66 (0.93%)

CTIC

CTI BioPharma

$3.71

(0.00%)

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 11

    Apr

  • 30

    May

BSX Boston Scientific
$26.70

0.22 (0.83%)

02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/23/18
PIPR
02/23/18
INITIATION
Target $31
PIPR
Overweight
Boston Scientific assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of Boston Scientific with an Overweight rating and $31 price target. While the Lotus delay has been in focus, the company's core MedSurg business is a steady high single to low double-digit grower and is underappreciated by the Street, O'Brien tells investors in a research note. He also believes Boston Scientific has a "number of compelling other products" in interventional cardiology and peripheral interventions.
01/09/18
LEER
01/09/18
NO CHANGE
LEER
Outperform
Boston Scientific should outperform on 'strong beat,' says Leerink
Leerink analyst Danielle Antalffy notes that Boston Scientific preannounced better than expected Q4 results. The analyst sees this quarterly performance as particularly encouraging, given the fact that Boston Scientific delivered outperformance across all business segments despite facing a tough comp. Antalffy expects the stock to outperform on this strong beat, and continues to believe Boston Scientific represents "one of the most attractive" top-line growth stories in large-cap MedTech. She reiterates an Outperform rating on the shares.
01/05/18
RBCM
01/05/18
UPGRADE
Target $31
RBCM
Top Pick
Boston Scientific upgraded to Top Pick at RBC Capital
As reported earlier, RBC Capital analyst Glenn Novarro upgraded Boston Scientific to Top Pick from Outperform, keeping his $31 price target. Novarro says the Q4 earnings expected out on February 1st will be a positive catalyst in addressing concerns around 2018 outlook in late November when the company announced another delay in its LOTUS Edge system.
MSI Motorola Solutions
$105.89

1.16 (1.11%)

02/23/18
CHLM
02/23/18
NO CHANGE
Target $17
CHLM
Buy
Immersion price target raised to $17 from $15 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss says Immersion's (IMMR) guidance for 2018 is better than expected on the heels of the settlement Apple (AAPL) settlement. In a research note to clients, Stoss, who raised his price target to $17 from $15 and has a Buy rating on shares, said the implied Apple settlement appears to be towards the high end or above his previous $25M-$30M expectation. Due to ASC606 accounting, a portion of the Apple settlement will be taken in Q1 with the rest ratable over the life of the contract. He also noted that litigation spend guidance was a vast improvement vs. actual spend in 2017. He looks for additional pending lawsuit settlements with Samsung (SSNLF), Fitbit (FIT) and Motorola (MSI) in the coming months and years, penetration into new markets like China and growing adoption in automotive to drive the stock.
02/23/18
RAJA
02/23/18
INITIATION
Target $120
RAJA
Outperform
Motorola Solutions resumed with an Outperform at Raymond James
Raymond James analyst Adam Tindle resumed coverage on Motorola Solutions with an Outperform and $120 price target.
02/21/18
NRCS
02/21/18
NO CHANGE
Target $115
NRCS
Buy
Motorola Solutions analyst day next week may be a catalyst, says Northcoast
Northcoast Research analyst Keith Housum says Motorola Solutions' analyst day next week - the first in 3 years - could be a potential catalyst for the stock. Housum expects the management to share with investors its view on land mobile radio - LMR - technology, the complexity of which may have kept some investors away from Motorola shares. In a world of growing LTE networks, the analyst contends, LMR is critical, while the adoption of LTE is key to Motorola's long-term growth. Housum also expects the analyst day discussion to address the integration of recent acquisitions into its CommandCentral and Smart Public Safety Solutions offerings. The analyst keeps his Buy rating and $115 price target on the stock, saying he would not hesitate to buy Motorola shares heading into the Analyst Day.
02/09/18
02/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Motorola Solutions (MSI) initiated with a Neutral at JPMorgan. 2. Spero Therapeutics (SPRO) initiated with an Overweight at Cantor Fitzgerald. 3. County Bancorp (ICBK) initiated with a Neutral at DA Davidson. 4. Diplomat Pharmacy (DPLO) initiated with a Buy at Lake Street. 5. Pulmatrix (PULM) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALB Albemarle
$115.77

2.09 (1.84%)

01/19/18
JEFF
01/19/18
NO CHANGE
Target $150
JEFF
Buy
Albemarle price target lowered to $150 from $162 at Jefferies
Jefferies analyst Laurence Alexander lowered his price target for Albemarle to $150 saying broader economic growth is reducing the company's scarcity premium. He keeps a Buy rating on the shares. The analyst highlights yesterday's "trifecta of bad news." First, SQM (SQM) announced an agreement with CORFO that gives the company a Chilean quota for lithium production from 2018-2030. Second, Orocobre announced financing for an expansion in Argentina. And third, media reports in Chile highlighted some nationalist rhetoric from junior government officials threatening potential nationalization of lithium assets, someday. The analyst notes Albemarle shares now trade 20% below their peak, and FMC (FMC) 8% below.
01/30/18
UBSW
01/30/18
UPGRADE
Target $150
UBSW
Buy
Albemarle upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Albemarle to Buy with an unchanged price target of $150. The stock is down 23% from the November high despite no change to the outlook for lithium, Roberts tells investors in a research note. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. While spot prices may decline, the company is well protected due to its shift to longer term fixed-price contracts for the majority of its battery grade volumes, Roberts contends. He notes that UBS expects lithium demand to triple by 2025.
02/23/18
ARGS
02/23/18
INITIATION
Target $148
ARGS
Buy
Albemarle initiated with a Buy at Argus
Argus analyst Mike Jaffe initiated Albemarle with a Buy rating and a price target of $148. Jaffe says the company stands to benefit from "growing demand for lithium over the next several years, driven by accelerating production of batteries for electric vehicles". Despite the cyclicality of the company business, the analyst expects Albemarle to show steady EPS growth, while adding that its valuation based on the PEG ratio is also attractive.
01/30/18
01/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Strong Buy from Buy at Needham by analyst Kevin Caliendo, who contended that the stock remains underowned and, unlike its peers, yet to rally beyond the expectations of benefits from the tax changes. The analyst says the company's multiple has remained constant despite the expansion in the rest of the pharma services industry, forecasting EPS growth of 8%-10% beyond the modeled $8 per share in 2019. 2. JetBlue (JBLU) upgraded to Overweight from Neutral at JPMorgan by analyst Jamie Bakier who said the company's costs are "gradually coming under control" and its balance sheet is "sound." The analyst also upgraded United Continental (UAL) to Overweight from Underweight, saying the shares are the "cheapest in the sector and among the most washed out, having declined the most from recent highs." 3. Gilead (GILD) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who said that tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018. 4. Intel (INTC) upgraded to Buy from Neutral at Citi by analyst Christopher Danely, who said overly conservative guidance and poor sentiment from years of underperformance should drive estimates and the stock higher in the near term. He believes management's "new habit" of conservative guidance is good for the stock. 5. Albemarle (ALB) upgraded to Buy from Neutral at UBS by analyst John Roberts, who said the stock is down 23% from the November high despite no change to the outlook for lithium. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NEWR New Relic
$71.29

0.66 (0.93%)

02/23/18
WEDB
02/23/18
INITIATION
Target $86
WEDB
Outperform
New Relic initiated with an Outperform at Wedbush
Wedbush analyst Steve Koenig started New Relic with an Outperform rating and $86 price target, saying he sees a long runway ahead for growing its accounts and revenue per account. Koenig believes New Relic is well positioned to take share from legacy vendors, he tells investors.
02/07/18
NEED
02/07/18
NO CHANGE
Target $73
NEED
Buy
New Relic price target raised to $73 from $69 at Needham
Needham analyst Jack Andrews raised his price target on New Relic to $73 and kept his Buy rating after the company's "strong" Q3 results featuring its first quarterly profit. Andrews says the company is benefiting from digital transformation and that its fundamental business momentum is likely to remain robust on growth across large deals and strong momentum from new products. The analyst adds that the company is well positioned, "attacking a huge, early stage market opportunity".
02/07/18
OPCO
02/07/18
NO CHANGE
Target $66
OPCO
Outperform
New Relic price target raised to $66 from $57 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for New Relic to $66 from $57 after the company reported a "strong" Q3 ahead of Street expectations, delivering its first quarterly profit ahead of schedule. The analyst reiterates an Outperform rating on the shares.
02/07/18
SPHN
02/07/18
NO CHANGE
Target $70
SPHN
Overweight
New Relic price target raised to $70 from $60 at Stephens
Stephens analyst Jonathan Ruykhaver raised his price target on New Relic to $70 from $60 following the company's Q3 report, as he believes the performance provides evidence of the company's strong competitive position and execution. He keeps an Overweight rating on New Relic shares, adding that customer feedback also continues to validate its platform's positioning in the market.
CTIC CTI BioPharma
$3.71

(0.00%)

09/12/17
JEFF
09/12/17
INITIATION
Target $7.5
JEFF
Buy
CTI BioPharma initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started CTI BioPharma with a Buy rating and $7.50 price target. The analyst believes pacritinib is an approvable drug in the U.S. and sees "meaningful upside" from current share levels.
02/23/18
OPCO
02/23/18
INITIATION
Target $5
OPCO
Outperform
CTI BioPharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann initiated shares of CTI BioPharma with an Outperform rating and $5 price target. In a research note to investors, the analyst said she believes that the primary driver of value for the late-stage clinical biotechnology company is pacritinib, its compound for treatment of patients with myelofibrosis, and that since CTI BioPharma is currently dependent on pre-commercial products and is not yet profitable, she is focusing primarily on potential future revenue to value it. She expects CTI to introduce its first to products in the U.S. over the next several years, and sees total revenue growing to $467M in 2024.

TODAY'S FREE FLY STORIES

ACN

Accenture

$166.47

-0.47 (-0.28%)

, EADSY

Airbus

$0.00

(0.00%)

04:55
07/21/18
07/21
04:55
07/21/18
04:55
Conference/Events
Farnborough International to hold an airshow »

Farnborough International…

ACN

Accenture

$166.47

-0.47 (-0.28%)

EADSY

Airbus

$0.00

(0.00%)

ATI

Allegheny Technologies

$26.65

0.08 (0.30%)

BAESY

BAE Systems

$0.00

(0.00%)

BDRBF

Bombardier

$0.00

(0.00%)

CAE

CAE

$20.96

0.17 (0.82%)

CW

Curtiss-Wright

$125.79

-0.12 (-0.10%)

DASTY

Dassault Systemes

$0.00

(0.00%)

ESLT

Elbit Systems

$118.98

0.64 (0.54%)

LMT

Lockheed Martin

$322.76

3.09 (0.97%)

BA

Boeing

$354.92

-0.57 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 16

    Aug

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.